January 24, 2012 bioMérieux - 2011 Business Review
December 7, 2011 bioMérieux - Information on 2011 sales objective
November 18, 2011 bioMérieux Initiative to Support European Antibiotic Awareness Day
November 8, 2011 bioTheranostics’ CancerTYPE ID® Linked with Improved Clinical Outcome and Longer Survival
October 20, 2011 bioMérieux Business Review for the nine months ended September 30, 2011
September 6, 2011 bioMérieux - First-Half Results at June 30, 2011
July 27, 2011 New Study Reports: CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility CancerTYPE ID is Now a Covered Benefit for Medicare Part B Patients
July 22, 2011 Completion of the AES Chemunex group acquisition and filing of a tender offer for the AES Chemunex shares
July 19, 2011 bioMérieux - First-Half 2011 Business Review
July 19, 2011 bioMérieux Expands its Infectious Disease Offering with Acquisition of ARGENE, Specialized in Molecular Diagnostics for Immunocompromised Patients
BEST WISHES
Leveraging its unique theranostics assets, bioMérieux is a partner of choice for developing innovative personalized medicine solutions.
“We belong to a community" is one of bioMérieux's guiding principles. At each of our sites and subsidiaries throughout the world, our employees are joining forces to achieve bioMérieux's environmental goals.